These studies suggested that mutant PTEN causes an inadequate response to current anti-mutant BRAF kinase treatments in melanoma, supporting the notion that PTEN inactivation identifies a distinct clinically significant subset of melanomas, while implying that PTEN status may affect the molecular mechanism of late acquired resistance to BRAF inhibitor (BRAFi). This evidence concerns the gene BRAF and melanoma.